Anthony Cahn
- Safety, tolerability and pharmacokinetics (PK) of repeated doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist, in healthy adultsBy Rashmi Mehta, Kelly Hardes, Anthony Cahn, Amy Newlands, Alison Donald, Andrew Preece, Dennis Kelleher and Glenn CraterRashmi Mehta1Clinical Pharmacology Modelling Simulation, GlaxoSmithKline, Research Triangle Park, United StatesKelly Hardes2Clinical Pharmacology Science and Study Operations, GlaxoSmithKline, Uxbridge, United KingdomAnthony Cahn3Respiratory Medicine Discovery and Development, GlaxoSmithKline, Stevenage, United KingdomAmy Newlands4Discovery Biometrics, GlaxoSmithKline, Uxbridge, United KingdomAlison Donald5Quantitative Sciences, R&D, GlaxoSmithKline, Uxbridge, United KingdomAndrew Preece2Clinical Pharmacology Science and Study Operations, GlaxoSmithKline, Uxbridge, United KingdomDennis Kelleher6Respiratory Medicine Discovery and Development, GlaxoSmithKline, Research Triangle Park, United StatesGlenn Crater7Respiratory and Immuno-Inflammation Medicine Development Center, GlaxoSmithKline, Research Triangle Park, United States
- Safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of GSK573719 inhalation powder in healthy subjectsBy Anthony Cahn, Rosalind Lovick, Amy Newlands, Amanda Deans, Isabelle Pouliquen, Andrew Preece, Dennis Kelleher, Rashmi Mehta and Ruth Tal-SingerAnthony Cahn1Respiratory Medicine Discovery and Development, GlaxoSmithKline, Stevenage, United KingdomRosalind Lovick2Clinical Pharmacology Science and Study Operations, GlaxoSmithKline, Uxbridge, United KingdomAmy Newlands3Discovery Biometrics, GlaxoSmithKline, Uxbridge, United KingdomAmanda Deans4Statistics, GlaxoSmithKline, Uxbridge, United KingdomIsabelle Pouliquen5Clinical Pharmacology Modelling and Simulation, GlaxoSmithKline, Uxbridge, United KingdomAndrew Preece2Clinical Pharmacology Science and Study Operations, GlaxoSmithKline, Uxbridge, United KingdomDennis Kelleher6Respiratory Medicines Discovery and Development, GlaxoSmithKline, Research Triangle Park, United StatesRashmi Mehta7Clinical Pharmacology Modelling and Simulation, GlaxoSmithKline, Research Triangle Park, United StatesRuth Tal-Singer8Respiratory Medicines Discovery and Development Centre, GlaxoSmithKline, King of Prussia, United States
- Safety, pharmacokinetics (PK) and pharmacodynamics (PD) of single doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist (LAMA), in patients with COPDBy Rashmi Mehta, Amy Newlands, Dennis Kelleher, Andrew Preece, Anthony Cahn and Glenn CraterRashmi Mehta1Clinical Pharmacology Modelling Simulation, GlaxoSmithKline, Research Triangle Park, United StatesAmy Newlands2Discovery Biometrics, GlaxoSmithKline, Uxbridge, United KingdomDennis Kelleher3Respiratory Medicines Discovery and Development, GlaxoSmithKline, Research Triangle Park, United StatesAndrew Preece4Clinical Pharmacology Science and Study Operations, GlaxoSmithKline, Uxbridge, United KingdomAnthony Cahn5Respiratory Medicine Discovery and Development, GlaxoSmithKline, Stevenage, United KingdomGlenn Crater6Respiratory and Immuno-Inflammation Medicine Development Center, GlaxoSmithKline, Research Triangle Park, United States
- Phase II study of once-daily GSK573719 inhalation powder, a new long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD)By Dennis Kelleher, Andrew Preece, Rashmi Mehta, Alison Donald, Kelly Hardes, Anthony Cahn and Glenn CraterDennis Kelleher1Respiratory Medicines Discovery and Development, GlaxoSmithKline, Research Triangle Park, United StatesAndrew Preece2Clinical Pharmacology Science and Study Operations, GlaxoSmithKline, Uxbridge, United KingdomRashmi Mehta3Clinical Pharmacology Modelling Simulation, GlaxoSmithKline, Research Triangle Park, United StatesAlison Donald4Quantitative Sciences, R&D, GlaxoSmithKline, Uxbridge, United KingdomKelly Hardes2Clinical Pharmacology Science and Study Operations, GlaxoSmithKline, Uxbridge, United KingdomAnthony Cahn5Respiratory Medicine Discovery and Development, GlaxoSmithKline, Stevenage, United KingdomGlenn Crater6Respiratory and Immuno-Inflammation Medicine Development Center, GlaxoSmithKline, Research Triangle Park, United States
- Safety, tolerability and pharmacokinetics (PK) of single and repeat nebulised doses of a novel phosphoinositide 3-kinase δ inhibitor (PI3Kδ), GSK2269557, administered to healthy male subjects in a phase I studyBy Robert Wilson, Anthony Cahn, Amanda Deans, Iain McSherry, Curtis Rambaran, Ana Sousa and Darren WilbrahamRobert Wilson1Research and Development, GlaxoSmithKline, Stevenage, Hertfordshire, United KingdomAnthony Cahn1Research and Development, GlaxoSmithKline, Stevenage, Hertfordshire, United KingdomAmanda Deans1Research and Development, GlaxoSmithKline, Stevenage, Hertfordshire, United KingdomIain McSherry1Research and Development, GlaxoSmithKline, Stevenage, Hertfordshire, United KingdomCurtis Rambaran1Research and Development, GlaxoSmithKline, Stevenage, Hertfordshire, United KingdomAna Sousa1Research and Development, GlaxoSmithKline, Stevenage, Hertfordshire, United KingdomDarren Wilbraham2Quintiles Drug Reasearch Unit, Quintiles, London, Greater London, United Kingdom
- Safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single (SD) and repeat (RD) inhaled doses of a novel phosphoinositide 3-kinase δ inhibitor (PI3Kδ), GSK2269557, administered to healthy smokersBy Robert Wilson, Anthony Cahn, Mickael Montembault, Joanne Green, Naila Musani, Malcolm Begg, Amanda Deans, Jane Gilbert, Sheelan Ahmed, Anna Kielkowska, Jonathan Clark, Malcolm Boyce, Edith M. Hessel and Pietro VentrescaRobert Wilson1Research and Development, GlaxoSmithKline, Stevenage, Hertfordshire, United KingdomAnthony Cahn1Research and Development, GlaxoSmithKline, Stevenage, Hertfordshire, United KingdomMickael Montembault1Research and Development, GlaxoSmithKline, Stevenage, Hertfordshire, United KingdomJoanne Green1Research and Development, GlaxoSmithKline, Stevenage, Hertfordshire, United KingdomNaila Musani1Research and Development, GlaxoSmithKline, Stevenage, Hertfordshire, United KingdomMalcolm Begg1Research and Development, GlaxoSmithKline, Stevenage, Hertfordshire, United KingdomAmanda Deans1Research and Development, GlaxoSmithKline, Stevenage, Hertfordshire, United KingdomJane Gilbert1Research and Development, GlaxoSmithKline, Stevenage, Hertfordshire, United KingdomSheelan Ahmed1Research and Development, GlaxoSmithKline, Stevenage, Hertfordshire, United KingdomAnna Kielkowska3Signalling Group, The Babraham Institute, Cambridge, Cambridgeshire, United KingdomJonathan Clark3Signalling Group, The Babraham Institute, Cambridge, Cambridgeshire, United KingdomMalcolm Boyce2Medical Director, HMR Ltd, London, Central London, United KingdomEdith M. Hessel1Research and Development, GlaxoSmithKline, Stevenage, Hertfordshire, United KingdomPietro Ventresca1Research and Development, GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom
- Improvement in FEV1 after acute COPD exacerbations are driven more by changes in hyperinflation than changes in proximal airway volumeBy Cedric Van Holsbeke, Wim Vos, Wouter Van Geffen, Huib Kerstjens, Massimo Pistolesi, Omar Usmani, Bita Hajian, Anthony Cahn, Jan De Backer and Wilfried De BackerCedric Van Holsbeke1Respiratory, FLUIDDA, Kontich, BelgiumWim Vos1Respiratory, FLUIDDA, Kontich, BelgiumWouter Van Geffen2Faculty of Medical Sciences, Lung Diseases, University of Gronigingen, Gronigingen, NetherlandsHuib Kerstjens2Faculty of Medical Sciences, Lung Diseases, University of Gronigingen, Gronigingen, NetherlandsMassimo Pistolesi3Department of Experimental and Clinical Medicine, University of Firenze, Firenze, ItalyOmar Usmani4Faculty of Medicine, National Heart & Lung Institute, Imperial College London, London, United KingdomBita Hajian5Departement of Pulmonary Medicine, University of Antwerp, Edegem, BelgiumAnthony Cahn6Respiratory Medicine Discovery and Development, GlaxoSmithKline, Stevenage Herts, United KingdomJan De Backer1Respiratory, FLUIDDA, Kontich, BelgiumWilfried De Backer5Departement of Pulmonary Medicine, University of Antwerp, Edegem, Belgium
- Changes in functional respiratory imaging (FRI) endpoints correlate with changes in patient reported outcomes (PRO) after recovering from acute COPD exacerbationBy Wim Vos, Cedric Van Holsbeke, Wouter Van Geffen, Huib Kerstjens, Massimo Pistolesi, Omar Usmani, Bita Hajian, Anthony Cahn, Jan De Backer and Wilfried De BackerWim Vos1Respiratory, FLUIDDA, Kontich, BelgiumCedric Van Holsbeke1Respiratory, FLUIDDA, Kontich, BelgiumWouter Van Geffen2Faculty of Medical Sciences, Lung Diseases, University of Gronigingen, Gronigingen, NetherlandsHuib Kerstjens2Faculty of Medical Sciences, Lung Diseases, University of Gronigingen, Gronigingen, NetherlandsMassimo Pistolesi3Department of Experimental and Clinical Medicine, University of Firenze, Firenze, ItalyOmar Usmani4Faculty of Medicine, National Heart & Lung Institute, Imperial College London, London, United KingdomBita Hajian5Departement of Pulmonary Medicine, University of Antwerp, Edegem, BelgiumAnthony Cahn6Respiratory Medicine Discovery and Development, GlaxoSmithKline, Stevenage Herts, United KingdomJan De Backer1Respiratory, FLUIDDA, Kontich, BelgiumWilfried De Backer5Departement of Pulmonary Medicine, University of Antwerp, Edegem, Belgium
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.
